BEAT News and Press, Heartbeam Inc. From 12/29/22

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today issued a letter to shareholders from its Chief Executive Officer and Founder, Branislav Vajdic, PhD....

BEAT has developed technology that collects data to synthesize a 12-lead 3D vector electrocardiogram (“VECG”) The device provides physicians with a 12-lead ECG associated with chest pain compared to a baseline ECG for the patient This key data enables physicians to assess whethe...

BEAT continues impressive march forward in developing a suite of products designed to detect heart attacks anytime, anywhere Inventions protected by patent enable proprietary 3D vector ECG technology to be built into a smartwatch Projections for global smartwatch and wearables medical-device ...

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is partnering with medical device manufacturing company Evolve Manufacturing Technologies to buil...

Partnership Positions AIMIGo for Early Market Testing in Q2 2023 After Expected FDA Clearance HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, ...

HeartBeam (NASDAQ: BEAT) was recently named the winner of the annual Cardiovascular Innovations (“CVI”) 2022 Information Summit and Shark Tank Competition, an annual conference that focuses on innovative health solutions for cardiology clinicians. Awards presented at the conference...

New Chief Medical Officer will play a major role in defining best paths to adoption, clinical strategies, and partnerships Dr. Fitzgerald serves as director of the Center for Cardiovascular Technology and of the Cardiovascular Core Analysis Laboratory at Stanford University Medical Scho...

BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”) Innovation Summit and Shark Tank Competition Company’s presentation included an overview of its HeartBeam AIMI™ platform, which aids in more precise heart attack diagnosis HeartBeam is buildin...

HeartBeam ( NASDAQ: BEAT ) is trading 9% higher after it received patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias by the U.S. Patent and Trademark Office. The co...

Patent Opens Pathway to Disruptive Ischemia and Arrhythmia Detection Product in Multi-billion Dollar Wearables Device Market HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for...